Gilles Bernard Tremblay

This inventor holds 29 USPTO granted patents and 13 published patent applications, plus 18 CIPO patents and 11 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Alethia Biotherapeutics Inc., Adc Therapeutics Sa, Daiichi Sankyo Company, Limited. Active years: 1981-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gilles Bernard Tremblay. Retrieved from https://idiyas.com/inventor/gilles-bernard-tremblay

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 13)

% Patents Active = 79.3

CIPO Patents = 18 (Patent Applications = 12)

EPO Patents = 11 (Patent Applications = 14)

Average Co-Inventor Count = 3.1

ph-index = 7

Forward Citations = 235(Granted Patents)

Location History:

Ville Ste-Catherine, Québec, CA (2006)
Quebec, CA (1981 - 2012)
La Praire, CA (2014)
La Prairie, CA (2011 - 2021)

Company Filing History:

19 out of 19

Alethia Biotherapeutics Inc.

Daiichi Sankyo Company, Limited

patents

4. 1 out of 1,039

National Research Council of Canada

patents

5. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1981-2021

Loading Chart...

Areas of Expertise:

Cancer Treatment

Antibodies

Siglec-15

Clusterin Inhibitors

Bone Remodeling

Polynucleotides

Tumor Volume Reduction

Osteoclast Differentiation

KAAG1

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11084872 - Method for treating breast cancer (2021-08-10),

2. 10597450 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2020-03-24),

3. RE47672 - Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 (2019-10-28),

4. 9855291 - Anti-kidney associated antigen 1 (KAAG1) antibodies (2018-01-02),

5. 9828426 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2017-11-28),

6. 9822170 - Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer (2017-11-21),

7. 9695419 - Polynucleotides and polypeptide sequences involved in the process of bone remodeling (2017-07-04),

8. 9617337 - Siglec-15 antibodies in treating bone loss-related disease (2017-04-11),

9. 9512211 - Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume (2016-12-06),

10. 9493562 - Anti-Siglec-15 antibodies (2016-11-15),

11. 9393302 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2016-07-19),

12. 9388242 - Nucleic acids encoding anti-Siglec-15 antibodies (2016-07-12),

13. 9067984 - Methods of impairing osteoclast differentiation using antibodies that bind Siglec-15 (2015-06-30),

14. 9040246 - Methods of making antibodies that bind polypeptides involved in the process of bone remodeling (2015-05-26),

15. 8937163 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2015-01-20),

Title: **Gilles Bernard Tremblay: Innovating in Cancer Treatment**

Introduction

Gilles Bernard Tremblay is an accomplished inventor based in La Prairie, CA, known for his impactful contributions to cancer treatment through innovative biotherapeutics. With an impressive portfolio of 26 patents, Tremblay's work focuses on targeting specific cancer cells to enhance treatment efficacy.

Latest Patents

Among his latest patents, Tremblay has developed a method for treating breast cancer, specifically targeting triple-negative breast cancer cells that lack ER protein expression, PgR protein expression, and/or show absence of HER2 protein over-expression. His research introduces an anti-KAAG1 antibody that is effective in killing these specific breast cancer cells upon delivering a therapeutic moiety. Additionally, he has disclosed novel antibodies and antigen binding fragments that specifically bind to KAAG1 for the detection and therapeutic treatment of KAAG1-expressing cancer cells. This innovative approach has potential applications in treating various cancers such as ovarian, renal, lung, colorectal, breast, brain, prostate cancers, and melanomas.

Career Highlights

Tremblay's career highlights include his influential roles in notable companies such as Alethia Biotherapeutics Inc. and ADC Therapeutics SA, where he has advanced his research and development efforts in biotherapeutics.

Collaborations

Throughout his career, Tremblay has collaborated with esteemed colleagues, including Mario Filion and Roy Rabindranauth Sooknanan. These partnerships have allowed for the exchange of ideas and innovation within the field of cancer research.

Conclusion

Gilles Bernard Tremblay stands out as a visionary inventor in the realm of cancer treatment. His commitment to developing innovative therapies shows promise in enhancing the lives of patients affected by various forms of cancer. As he continues to contribute to the scientific community, his patents and research will undoubtedly pave the way for future advancements in medical treatments.

Profile summary based on public USPTO records.